SOPHiA GENETICS SA SOPH

SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75. Recent research linking the company’s role in data driven oncology and rare disease diagnostics with Q2 results and higher guidance has supported price targets in a US$9 to US$12 range, while still flagging execution and valuation risk. Read on to see how these shifting targets feed into the broader SOPHiA GENETICS story and how you can track the narrative from...

SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven tools...

SOPHiA GENETICS is tasked with developing its Solid Tumor application as a decentralised companion diagnostic.

Sophia Genetics SA (SOPH) delivers 27% revenue growth, raises full-year guidance, and announces landmark AstraZeneca CDX deals and MSK joint venture.

Sophia Genetics announced a partnership with AstraZeneca to develop two cancer diagnostic tests and also raised its full-year revenue forecast.

SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026.

SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).

SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

SOPHiA GENETICS SA (NASDAQ:SOPH) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 4, 2026, SOPHiA GENETICS SA (NASDAQ:SOPH) reported that it signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a proposed joint venture aimed at building a precision medicine hub […]

SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted all proposals on the agenda, electing Dr. Jurgi Camblong as the Executive Chairman of the Board of Directors with 99.79% of the votes, and Ross Muken as a member of the Board of Directors for the first time with 99.88% of the votes. Mr. Muken will assume the role of Chief Executive Officer, effective July 1, 2026.

SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares